ADMA Biologics (NASDAQ:ADMA) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS

ADMA Biologics (NASDAQ:ADMA) released its quarterly earnings results on Monday. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.01), Zacks reports. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%.

ADMA Biologics Trading Down 3.4 %

Shares of ADMA traded down $0.56 during mid-day trading on Monday, reaching $15.83. The stock had a trading volume of 3,936,858 shares, compared to its average volume of 2,290,697. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The business’s fifty day moving average is $16.73 and its 200 day moving average is $17.99. ADMA Biologics has a 52-week low of $5.52 and a 52-week high of $23.64. The firm has a market cap of $3.74 billion, a price-to-earnings ratio of 56.54 and a beta of 0.75.

Wall Street Analyst Weigh In

ADMA has been the subject of a number of research analyst reports. HC Wainwright increased their target price on ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a report on Friday, November 8th. Raymond James raised their price objective on ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a report on Friday, November 8th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.